drugset
Drugs / IM19
last change Aug 2025 re-read 2 minutes ago

IM19

also known as IM19CAR-T

Cell therapy targets CD19

Developed for
leukemia · aggressive B-cell non-Hodgkin lymphoma · hematopoietic and lymphoid cell neoplasm · idiopathic membranous glomerulonephritis · IgA glomerulonephritis · non-Hodgkin lymphoma
Investigated by
Beijing Immunochina Medical Science & Technology Co., Ltd. · Jiangsu Simcere Pharmaceutical Co., Ltd. · Peking University Cancer Hospital & Institute

Trials 7 · a red edge is where a trial was stopped

today NCT06690359 · Ph 0 NCT04440436 · Ph 1/2 NCT04336501 · not/applicable NCT03528421 · Ph 1 NCT03344705 · Ph 1 NCT03173417 · Ph 1/2 NCT03142646 · Ph 1/2
2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT06690359 Dec 2024 → Aug 2025 overdue IgA glomerulonephritis, idiopathic membranous glomerulonephritis Beijing Immunochina Medical Science & Technology Co., Ltd. Not yet recruiting No outcome recorded
Phase 12 trials
Phase 1 NCT03528421 May 2018 → Apr 2020 non-Hodgkin lymphoma Beijing Immunochina Medical Science & Technology Co., Ltd. Unknown No outcome recorded
Phase 1 NCT03344705 Aug 2017 → Oct 2020 hematopoietic and lymphoid cell neoplasm Beijing Immunochina Medical Science & Technology Co., Ltd. Unknown No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT04440436 Jun 2020 → Jun 2022 overdue aggressive B-cell non-Hodgkin lymphoma Beijing Immunochina Medical Science & Technology Co., Ltd. Recruiting No outcome recorded
Phase 1/2 NCT03173417 May 2017 → May 2019 leukemia Beijing Immunochina Medical Science & Technology Co., Ltd. Completed No outcome recorded
Phase 1/2 NCT03142646 Aug 2016 → Jun 2018 leukemia Beijing Immunochina Medical Science & Technology Co., Ltd. Unknown No outcome recorded
Phase not applicable1 trial
— NCT04336501 Jan 2019 → Dec 2021 leukemia Beijing Immunochina Medical Science & Technology Co., Ltd. Unknown No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as IM19 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04440436 ↗
3

NCT03528421 ↗

NCT04336501 ↗

NCT06690359 ↗
Known as IM19CAR-T “A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of IM19CART cells administered intravenously.” NCT03142646 ↗
4

“receive IM19CAR-T cell infusion therapy” NCT06690359 ↗

NCT03142646 ↗

NCT03173417 ↗

NCT03344705 ↗
Modality Cell therapy “T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor” NCT03142646 ↗
Route Intravenous “single infusion of IM19CART cells administered intravenously” NCT03142646 ↗
Target CD19 “Anti-CD19 Chimeric Antigen Receptor” NCT03142646 ↗